Search
We have quantified the relative influence of perinatal risk factors associated with skin infection hospitalisations in WA children
Documenting carer, service provider and healthcare practitioner perspectives on skin infections provides more understanding of the context of treatment decisions
Here, the role, status, and directions in Group A Streptococcus vaccines research are discussed
Few children and adolescents receiving BPG as secondary prophylaxis will achieve concentrations >0.02 mg/L for the majority of the time between injections
This study will identify the incidence of true Group A Streptococcal pharyngitis and serological responses to Group A Streptococcal GAS skin infections
The WHF echocardiographic criteria enable reproducible categorisation of echocardiograms as definite RHD versus no or borderline RHD
We identified the existence of more than 290 clinically associated genomic phylogroups across 22 countries, highlighting challenges in designing vaccines of global utility
Indigenous patients are substantially underrepresented in care by services participating in the nationwide specialist palliative care Collaboration, likely reflecting widespread access barriers.
Systematic review of the treatment, prevention and public health control of skin infections in resource-limited settings where skin infections are endemic
Streptococcus pneumoniae causes substantial morbidity and mortality among children. The introduction of pneumococcal conjugate vaccines (PCV) has the potential to dramatically reduce disease burden. As with any vaccine, it is important to evaluate PCV impact, to help guide decision-making and resource-allocation.